HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 08, August 2017 – Eye – the Window to your Soul       » Palm-Sized PCR Device for Rapid Real-Time Detection of Viruses       » Scientists Uncover New Mechanism for Diabetic Neuropathy       » China Enlists AI to Diagnose Breast Cancer       » Philips and Singapore Institute of Advanced Medicine Holdings Sign Agreement to Open First-of-its-kind Oncology Center in Singapore       » Guardian Partners with MyDoc to Address Singapore's Population Health Needs through Integrating Technology and Self-Care       » Database Boosts Shanghai's Technology Aim      
EYE in CHINA
Catalent announces major China expansion with two new facilities
Catalent Pharma Solutions, the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic and consumer health products, announced two joint ventures in China for its Softgel Technologies and Clinical Supply Solutions businesses. Catalent continues to expand its global leadership by providing access to drug delivery and clinical trial capabilities for customers in Asia Pacific. The company intends to make additional investments in these two facilities over the next several years to broaden its offerings in the Chinese market.

First, Catalent has agreed to acquire, pending regulatory approvals, a majority share in Haining-based, privately held Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd. The business produces nutritional softgel products for Chinese and Asia Pacific markets, and employs 120 staff. Catalent intends to work with regulators for future expansion into OTC and prescription softgel manufacturing in China.

In the second announcement, Catalent and ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, have formed a joint-venture called Catalent (Shanghai) Clinical Trial Supplies Co., Ltd. A new 31,000 sq ft facility in Shanghai (currently under construction) will be the first in China to provide end-to-end solutions for clinical trial supplies, including comparator sourcing, primary and secondary packaging and labeling, and storage and distribution.

Commenting on both investments, Catalent’s President & CEO, John Chiminski said, “As part of our growth strategy, these initial steps enable us to better serve the important Chinese market for both global and domestic customers. Our clients and their patients will benefit from access to Catalent’s advanced technologies and solutions, together with best-in-class innovation, reliable supply and quality compliance.”

“We are delighted to be working with Catalent, a world leader in drug development services and clinical supply services,” said Michael Hui, founder and CEO of ShangPharma. “This cooperation will enable both ShangPharma and Catalent to better serve our multinational pharmaceutical customers through tailored, integrated solutions.”

The Chairman & CEO of Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd, Jiang Renfei commented, “The combination of Catalent’s unparalleled track record of Softgel innovation and commercial success, and our deep understanding of the local market, will provide extensive benefits for our customers”.

No other terms of the transactions have been disclosed.

Click here for the complete issue.

NEWS CRUNCH  
news Vitafoods Asia 2017 heralds a new future of innovation
news Sanner receives Zero Defect Award
news AdAlta pioneers novel drug for rare lung disease
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy